BR9814956A - Inibidores de benzotiazol da tirosina cinase de proteìna - Google Patents

Inibidores de benzotiazol da tirosina cinase de proteìna

Info

Publication number
BR9814956A
BR9814956A BR9814956-3A BR9814956A BR9814956A BR 9814956 A BR9814956 A BR 9814956A BR 9814956 A BR9814956 A BR 9814956A BR 9814956 A BR9814956 A BR 9814956A
Authority
BR
Brazil
Prior art keywords
tyrosine kinase
protein tyrosine
inhibitors
benzothiazole
benzothiazole inhibitors
Prior art date
Application number
BR9814956-3A
Other languages
English (en)
Inventor
Jagabandhu Das
Joel C Barrish
John Wityak
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR9814956A publication Critical patent/BR9814956A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"INIBIDORES DE BENZOTIAZOL DA TIROSINA CINASE DE PROTEìNA" Novos benzotiazóis e sais dos mesmos, composições farmacêuticas contendo tais compostos, e métodos de usar tais compostos no tratamento de distúrbios associados com a tirosina cinase de proteína, tais como os distúrbios imunológicos.
BR9814956-3A 1997-11-10 1998-11-02 Inibidores de benzotiazol da tirosina cinase de proteìna BR9814956A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6504297P 1997-11-10 1997-11-10
PCT/US1998/023204 WO1999024035A1 (en) 1997-11-10 1998-11-02 Benzothiazole protein tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
BR9814956A true BR9814956A (pt) 2000-10-03

Family

ID=22059964

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814956-3A BR9814956A (pt) 1997-11-10 1998-11-02 Inibidores de benzotiazol da tirosina cinase de proteìna

Country Status (25)

Country Link
US (1) US6825355B2 (pt)
EP (1) EP1037632B1 (pt)
JP (1) JP2001522800A (pt)
KR (1) KR20010031912A (pt)
CN (1) CN1290165A (pt)
AR (1) AR017588A1 (pt)
AT (1) ATE315394T1 (pt)
AU (1) AU744281B2 (pt)
BR (1) BR9814956A (pt)
CA (1) CA2309319A1 (pt)
DE (1) DE69833224T2 (pt)
ES (1) ES2256969T3 (pt)
HU (1) HUP0102101A3 (pt)
ID (1) ID24289A (pt)
IL (1) IL135176A0 (pt)
NO (1) NO20002121L (pt)
NZ (1) NZ503491A (pt)
PE (1) PE129799A1 (pt)
PL (1) PL340727A1 (pt)
RU (1) RU2212407C2 (pt)
TR (1) TR200001312T2 (pt)
TW (1) TW510898B (pt)
UY (1) UY25242A1 (pt)
WO (1) WO1999024035A1 (pt)
ZA (1) ZA9810219B (pt)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214836A1 (en) * 1998-05-29 2004-10-28 Cheresh David A. Method of treatment of myocardial infarction
US20060258686A1 (en) * 1998-05-29 2006-11-16 Cheresh David A Method of treatment of myocardial infarction
US20030130209A1 (en) * 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
WO2000062778A1 (en) * 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
WO2001025238A2 (en) * 1999-10-06 2001-04-12 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
MXPA02007632A (es) * 2000-02-07 2004-08-23 Abbott Gmbh & Co Kg Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa.
GB0003254D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
CZ2003182A3 (cs) 2000-06-21 2003-06-18 F. Hoffmann-La Roche Ag Deriváty benzothiazolu
CA2417635C (en) * 2000-08-11 2008-02-05 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US7238813B2 (en) 2000-11-29 2007-07-03 Smithkline Beecham Corporation Chemical compounds
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
YU37904A (sh) 2001-11-09 2006-08-17 Boehringer Ingelheim Pharmaceuticals Inc. Benzimidazoli kao korisni inhibitori proteinske kinaze
US6734179B2 (en) * 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
JP2005536533A (ja) * 2002-08-08 2005-12-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換ベンゾイミダゾール化合物
JP2006502133A (ja) * 2002-08-10 2006-01-19 アステックス、セラピューティックス、リミテッド サイクリン依存キナーゼ（ｃｄｋ）インヒビターとしての３−（カルボニル）１ｈ−インダゾール化合物
SE0202429D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
SE0202464D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Use of compounds
EP2426122A1 (en) * 2002-10-24 2012-03-07 Merck Patent GmbH Methylene urea derivative as RAF kinasse inhibitors
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
EP1597256A1 (en) * 2003-02-21 2005-11-23 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
EP1608639A2 (en) * 2003-02-28 2005-12-28 Bayer Pharmaceuticals Corporation Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
JP2006521345A (ja) * 2003-03-28 2006-09-21 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ニコチン性アセチルコリン受容体の正のアロステリック調節剤
US20050008640A1 (en) * 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
DK1626714T3 (da) 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
FR2864539B1 (fr) 2003-12-30 2012-10-26 Lvmh Rech Oligonucleotide et son utilisation pour moduler l'expression de la proteine-kinase c isoforme beta-1 comme agent de depigmentation cutanee
BRPI0506662B8 (pt) 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
WO2005075435A1 (en) 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
KR101099206B1 (ko) * 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
DE102004006808A1 (de) * 2004-02-11 2005-09-01 Grünenthal GmbH Substituierte 4,5,6,7-Tetrahydro-benzothiazol-2-ylamin-Verbindungen
WO2005079791A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
FR2868421B1 (fr) 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
US7550499B2 (en) * 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP4668265B2 (ja) 2004-05-24 2011-04-13 エフ．ホフマン−ラ ロシュ アーゲー ４−ヒドロキシ−４−メチル−ピペリジン−１−カルボン酸（４−メトキシ−７−モルホリン−４−イル−ベンゾチアゾール−２−イル）−アミド
SE0401970D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Novel compounds
WO2006048172A1 (en) 2004-11-05 2006-05-11 F. Hoffmann-La Roche Ag Process for preparation of isonicotinic acid derivatives
SE0403117D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab New compounds 1
US7514460B2 (en) 2004-12-22 2009-04-07 4Sc Ag Benzazole analogues and uses thereof
ATE499370T1 (de) * 2005-01-19 2011-03-15 Bristol Myers Squibb Co 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3- aminderivate und verwandte verbindungen als p2y1- rezeptor-hemmer zur behandlung thromboembolischer erkrankungen
JP5066514B2 (ja) * 2005-03-14 2012-11-07 ハイ ポイント ファーマシューティカルズ，エルエルシー ベンズアゾール誘導体、組成物及びβ−セクレターゼ阻害剤としての使用方法
KR100973609B1 (ko) 2005-03-23 2010-08-03 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ2 길항제로서 아세틸렌일-피라졸로-피리미딘유도체
DE602006020871D1 (de) 2005-06-27 2011-05-05 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
US7728008B2 (en) * 2005-06-27 2010-06-01 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
ES2352796T3 (es) * 2005-06-27 2011-02-23 Bristol-Myers Squibb Company Antagonistas cíclicos unidos a c del receptor p2y1 útiles en el tratamiento de afecciones trombóticas.
US7714002B2 (en) * 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
ES2382815T3 (es) 2005-07-08 2012-06-13 Novo Nordisk A/S Dicicloalquilcarbamoil ureas como activadores de glucoquinasa
MX2008000255A (es) 2005-07-14 2008-04-02 Novo Nordisk As Activadores de urea glucocinasa.
DE602006013493D1 (de) 2005-09-27 2010-05-20 Hoffmann La Roche Oxadiazolylpyrazolopyrimidine als mglur2-antagonisten
US7960569B2 (en) * 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2008109459A1 (en) * 2007-03-02 2008-09-12 University Of Massachusetts Luciferins
JP2008222084A (ja) * 2007-03-14 2008-09-25 Yamaha Motor Electronics Co Ltd 電動ゴルフカーのブレーキ劣化検出方法及びこれを用いた電動ゴルフカー
WO2008124393A1 (en) * 2007-04-04 2008-10-16 Irm Llc Benzothiazole derivatives and their use as protein kinase inhibitors
FR2928547B1 (fr) 2008-03-13 2012-03-09 Lvmh Rech Extrait de l'orchidee brassocattle marcella koss et son utilisation en tant qu'actif de depigmentation cutanee
JP5779172B2 (ja) * 2009-04-02 2015-09-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ オートタキシン阻害剤
JP2012525389A (ja) 2009-04-27 2012-10-22 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換イソキノリン誘導体、医薬組成物、及びβ−セクレターゼ阻害剤としての使用方法
CN101701018B (zh) * 2009-11-05 2012-06-13 东南大学 2-(4-氨基喹唑啉基)苯并[d]噻唑类衍生物及其用途
WO2011119465A1 (en) * 2010-03-23 2011-09-29 High Point Pharmaceuticals, Llc Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
PL2730564T3 (pl) 2010-11-19 2018-09-28 Ligand Pharmaceuticals Inc. Heterocykliczne aminy i ich zastosowania
ES2586527T3 (es) * 2011-10-14 2016-10-17 Ambit Biosciences Corporation Compuestos heterocíclicos y uso de los mismos como moduladores del receptor de tirosina quinasas de tipo III
WO2014031441A1 (en) * 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydrofuran derivatives
CN103058954A (zh) * 2013-01-07 2013-04-24 盛世泰科生物医药技术(苏州)有限公司 一种[6-(5-氨基-2-甲基-苯氨基甲酰-苯并噻唑]-氨基甲酸叔丁酯的制备方法
EP2991967A1 (en) * 2013-03-20 2016-03-09 F. Hoffmann-La Roche AG Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors
WO2014168262A1 (en) * 2013-04-11 2014-10-16 D.D.P. Corporation Kinase inhibitors containing cyclopropane skeleton
EP2990027A1 (en) 2014-09-01 2016-03-02 Institut Curie Skin whitening peptide agents
JP6690543B2 (ja) * 2014-10-31 2020-04-28 宇部興産株式会社 置換ジヒドロピロロピラゾール化合物
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
ES2824450T3 (es) 2015-06-22 2021-05-12 Actelion Pharmaceuticals Ltd Compuestos de benzoxazol y de benzotiazol 2,5-disustituidos como inhibidores de la NADPH oxidasa 4
KR102089122B1 (ko) * 2016-08-25 2020-03-13 주식회사 엘지화학 디아민 화합물 및 이를 이용하여 제조된 플렉시블 소자용 기판
CN107021937B (zh) * 2017-03-27 2019-06-21 沈阳药科大学 苯并噻唑甲酰胺类化合物及其应用
EP3628674A4 (en) * 2017-05-04 2020-11-25 Shanghai Longwood Biopharmaceuticals Co., Ltd. BICYCLIC NUCLEOCAPSID INHIBITORS AND THEIR USE AS MEDICINAL PRODUCTS IN THE TREATMENT OF HEPATITIS B.
EP3638668A1 (en) * 2017-06-14 2020-04-22 European Molecular Biology Laboratory Bicyclic heteroaromatic urea or carbamate compounds for use in therapy
US10669246B2 (en) * 2017-10-02 2020-06-02 1ST Biotherapeutics, Inc. Benzothiazol compounds and methods using the same for treating neurodegenerative disorders
KR20210020866A (ko) 2018-06-12 2021-02-24 브이티브이 테라퓨틱스 엘엘씨 인슐린 또는 인슐린 유사체와 조합된 글루코키나제 활성제의 치료적 용도
CN115594671B (zh) * 2021-07-08 2024-03-15 沈阳药科大学 苯并噻唑类衍生物及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966706A (en) * 1971-01-27 1976-06-29 Ciba-Geigy Ag 2,6-Dihydroxy-3-cyano-4-methylpyridine containing azo dyes which contain a functional amino group
JPS50140442A (pt) * 1974-04-16 1975-11-11
JPS5632549A (en) * 1979-08-27 1981-04-02 Toyo Ink Mfg Co Ltd Pigment composition
JPS62194251A (ja) * 1986-02-20 1987-08-26 Konishiroku Photo Ind Co Ltd 保存安定性が改良されたハロゲン化銀写真感光材料
IL90337A0 (en) 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
US4970318A (en) * 1988-05-24 1990-11-13 Pfizer Inc. Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
JPH0667923B2 (ja) * 1989-05-11 1994-08-31 東洋紡績株式会社 新規なベンゾチアゾール誘導体
JP2869561B2 (ja) 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
WO1994019336A1 (en) * 1993-02-19 1994-09-01 Asahi Kasei Kogyo Kabushiki Kaisha Benzothiazolesulfonamide derivative, process for producing the same, and use thereof
US5496816A (en) 1994-03-14 1996-03-05 Merck & Co., Inc. Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
TW513418B (en) 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
EP0944645B1 (en) 1996-12-06 2005-03-09 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1beta CONVERTING ENZYME
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
WO1999031073A1 (fr) 1997-12-15 1999-06-24 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives de pyrimidine-5-carboxamide

Also Published As

Publication number Publication date
ES2256969T3 (es) 2006-07-16
AU1371999A (en) 1999-05-31
KR20010031912A (ko) 2001-04-16
PL340727A1 (en) 2001-02-26
NZ503491A (en) 2002-08-28
ZA9810219B (en) 2000-06-22
EP1037632B1 (en) 2006-01-11
CA2309319A1 (en) 1999-05-20
ATE315394T1 (de) 2006-02-15
PE129799A1 (es) 2000-03-08
AU744281B2 (en) 2002-02-21
US6825355B2 (en) 2004-11-30
EP1037632A1 (en) 2000-09-27
NO20002121D0 (no) 2000-04-26
DE69833224T2 (de) 2006-09-28
WO1999024035A1 (en) 1999-05-20
ID24289A (id) 2000-07-13
NO20002121L (no) 2000-05-09
JP2001522800A (ja) 2001-11-20
AR017588A1 (es) 2001-09-12
IL135176A0 (en) 2001-05-20
TR200001312T2 (tr) 2000-09-21
DE69833224D1 (en) 2006-04-06
RU2212407C2 (ru) 2003-09-20
HUP0102101A3 (en) 2002-11-28
TW510898B (en) 2002-11-21
EP1037632A4 (en) 2002-08-21
CN1290165A (zh) 2001-04-04
HUP0102101A2 (hu) 2001-11-28
UY25242A1 (es) 2001-08-27
US20020123484A1 (en) 2002-09-05

Similar Documents

Publication Publication Date Title
BR9814956A (pt) Inibidores de benzotiazol da tirosina cinase de proteìna
BR0009721A (pt) Inibidores de tirosina quinase de proteìna cìclica
PT1042305E (pt) Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas
BR9712321A (pt) Aminotiofenocarboxamidas
BR9812634A (pt) April - uma proteìna com efeitos de crescimento
DK1043995T3 (da) Inhibering af p38 kinaseaktivitet ved anvendelse af aryl- og heteroaryl-substituerede, heterocykliske urinstoffer
DE60321929D1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
FI961809A (fi) Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydro-2H-1-bentsopyraanit
BRPI0408782A (pt) inibidores cìclicos da proteìna tirosina cinase
PT1347971E (pt) Inibidores tiazolilicos de tirosina-cinases da familia tec
ES2178157T3 (es) Tratamiento de arritmias mediante la inhibicion de una proteina quinasa multifuncional dependiente de calcio/calmodulina.
YU49101A (sh) Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze
DK0725790T3 (da) Substituerede tetra- og pentapeptidinhibitorer af proteinfarnesyltransferase
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
FI972308A (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
ATE239709T1 (de) Racemisches huperzin a
GEP20001969B (en) Benzothiazine Dioxides as Endothelinn Antagonists
BR0213994A (pt) Derivados heterocìclicos de glicinamida e seus usos médicos
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
RS52011B (sr) Nova primena derivata taksoida
FI893681A (fi) N-2,3-butadienyltri- och tetra-aminoalkanderivat.
DK1007040T3 (da) Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O, 8O E 9O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007.